The compound induces apoptosis in cell lines harboring the JAK2 V617F, FLT3 wild-type and FLT3 internal tandem duplication (FLT3-ITD) mutation, and could potentially overcome FLT3 tyrosine kinase inhibition resistance in FLT3 mutated AML by means of excessive JAK2 inhibition.19, 28 The use of pacritinib is T-cell leukemias is also under examination in phase I trials.31 The gene discussed is JAK2; the disease is acute myeloid leukemia.